|Articles|May 2, 2020

FDA Issues Emergency Authorizations for Antibody Test and NASA Ventilator

Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of April 26, 2020.

New Total COVID-19 Antibody Test Receives FDA Emergency Use Authorization

The FDA has granted Bio-Rad Laboratories Emergency Use Authorization (EUA) for the company’s severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Total Ab test. This test is the first total antibody test that has received an EUA from the FDA.

The blood-based immunoassay test will be able to help clinicians identify whether an individual has antibodies against SARS-CoV-2, the virus associated with coronavirus disease 2019 (COVID-19).

The test will be available for use both manually or on an automated immunoassay platform.

Read the full article.

FDA Authorizes NASA Developed Ventilator for COVID-19

The FDA has added a ventilator developed by the National Aeronautics and Space Administration to the list of authorized ventilators under the FDA’s ventilator emergency use authorization.

The original emergency use authorization was issued out of concern related to an insufficient supply of FDA-approved ventilators for use in health care settings during the coronavirus disease 2019 (COVID-19) pandemic.

Read the full article.


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.